The DynamX Bioadaptor device was noninferior to DES for TLF overall, but a landmark analysis reveals a potential strength.

A study has found that sirolimus-coated balloons vs thin drug-eluting stents in in-stent restenosis show similar favorable clinical outcomes.

PRNewswire New Delhi [India]1 Translumina was incorporated in 2011 as a sales marketing company specialising in coronary ...

There is a variety of stent coatings with differing performance profiles that have been studied either in animal studies or clinical trials. The stent coatings can be broadly classified into three ...

The trial was set up to give DCBs their “best shot” in this patient group, says one researcher, but it’s tough to beat current DES.

Undergoing percutaneous coronary intervention (PCI) for narrowed arteries with a novel bioadaptor is at least as effective as ...

Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug-eluting stent (DES) and the efficacy and cost of using DESs versus bare-metal stents are discussed.

Translumina, established in 2011, focuses on coronary intervention devices and has expanded its manufacturing capabilities and product lines. The company aims to highlight Indian innovation in the ...

The vascular stents market is anticipated to grow from USD 11.4 billion in 2024 to USD 15.6 billion by 2029, with a CAGR of 6.5%. This growth ...

A bioresorbable vascular scaffold (BRS) with highly aligned microstructure and small-crystallite crystallinity can avoid high ...

Justin Hubbell is currently resting and recovering at a Des Moines hospital. He still bears the scars on his face from the beating he received Sunday morning. His older sister loves and is protective ...

Novel drug-coated balloons (DCB) did not outshine standard treatment with second generation drug-eluting stents (DES) as they were expected to, in a surprise finding of the first randomized trial ...